New drug combo aims to prevent dangerous transplant complication
NCT ID NCT04022239
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests the safety and best dose of bendamustine, given with or without cyclophosphamide, to prevent graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 25 participants will receive the drug after transplant, along with standard anti-rejection medicines. The goal is to find a dose that reduces GVHD without causing too many side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Could End-of-Life care for blood cancer patients be done at home?